Ainos' Japan Patent for VELDONA: A Game Changer in Antiviral Innovation

Ainos, Inc. (NASDAQ:AIMD), a pioneering healthcare company specializing in advanced AI-driven point-of-care testing and low-dose interferon therapeutics, has achieved a significant milestone with the approval of a pivotal invention patent in Japan for its groundbreaking oral interferon formulation, VELDONA®. This patent, titled "METHOD AND COMPOSITION OF TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION" (Patent No. 7619659), strengthens Ainos' global intellectual property (IP) portfolio and establishes the Company as a leader in differentiated antiviral solutions.

The global coronavirus therapeutics market is projected to exceed $16 billion by 2031, presenting a substantial opportunity for Ainos to redefine antiviral treatment standards with its patented sublingual interferon technology. The newly granted patent includes 15 key claims that deliver comprehensive protection for VELDONA®, covering its formulation, novel sublingual and buccal delivery mechanisms, and broad therapeutic applications.

Key Patent Highlights and Technical Innovations
The patented features emphasize:
• Low-Dose Administration: Using doses under 1,000 IU to optimize efficacy and minimize side effects.
• Innovative Delivery Mechanisms: Sublingual and buccal absorption for rapid action and enhanced bioavailability, eliminating the need for cold chain logistics.
• Multiple Delivery Formats: Lozenge, tablet, film, and spray options to cater to diverse patient preferences and market segments.

VELDONA's sublingual and buccal delivery mechanisms offer several key advantages that contribute to its market potential and patient compliance:
1. Rapid absorption and onset of action, enabling prompt intervention in treating viral infections.
2. Enhanced bioavailability, leading to higher drug concentrations in the systemic circulation and potentially improved efficacy.
3. Non-invasive and patient-friendly administration, significantly improving patient compliance, especially for chronic conditions or long-term treatments.
4. Cost-effective and scalable manufacturing, with reduced complexity and storage costs due to the elimination of cold chain requirements.
5. Broad applicability and market opportunities, expanding the total addressable market and driving substantial margin expansion as the company scales.
6. Potential licensing opportunities in different territories, further expanding the company's reach and revenue streams.

The elimination of cold chain requirements for VELDONA affects its manufacturing, distribution, and cost-effectiveness compared to traditional interferon therapies:
1. Manufacturing Complexity and Costs: Room-temperature stability reduces manufacturing complexity and potentially lowers manufacturing costs by 40-60%.
2. Distribution Economics: More cost-effective and efficient distribution, particularly in regions with healthcare infrastructure limitations, potentially yielding 30-40% higher gross margins compared to traditional interferon therapies.
3. Market Segmentation and Adoption: Multiple delivery formats allow for market segmentation and broader adoption, catering to different patient preferences and needs.

In conclusion, Ainos' Japan patent approval for VELDONA represents a significant milestone in antiviral therapeutics, particularly in the evolving $16 billion coronavirus market. The technology's key differentiator lies in its novel sublingual delivery system, which addresses major limitations of traditional interferon therapies. With its comprehensive IP protection, scalable manufacturing potential, and multiple market opportunities beyond coronavirus, Ainos is well-positioned to capitalize on this breakthrough and drive growth in the global antiviral market.